Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2008-01-04
2011-12-13
Goddard, Laura B (Department: 1642)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S138100
Reexamination Certificate
active
08075890
ABSTRACT:
Variant immunoglobulins, particularly humanized antibody polypeptides are provided, along with methods for their preparation and use. Consensus immunoglobulin sequences and structural models are also provided.
REFERENCES:
patent: 4753894 (1988-06-01), Frankel et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 4845198 (1989-07-01), Urdal et al.
patent: 4968603 (1990-11-01), Slamon et al.
patent: 5132405 (1992-07-01), Huston et al.
patent: 5169774 (1992-12-01), Frankel et al.
patent: 5225539 (1993-07-01), Winter
patent: 5530101 (1996-06-01), Queen et al.
patent: 5545403 (1996-08-01), Page
patent: 5545404 (1996-08-01), Page
patent: 5545405 (1996-08-01), Page
patent: 5558864 (1996-09-01), Bendig et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 5677171 (1997-10-01), Hudziak et al.
patent: 5693761 (1997-12-01), Queen et al.
patent: 5693762 (1997-12-01), Queen et al.
patent: 5714350 (1998-02-01), Co et al.
patent: 5720937 (1998-02-01), Hudziak et al.
patent: 5720954 (1998-02-01), Hudziak et al.
patent: 5725856 (1998-03-01), Hudziak et al.
patent: 5770195 (1998-06-01), Hudziak et al.
patent: 5772997 (1998-06-01), Hudziak et al.
patent: 5821337 (1998-10-01), Carter et al.
patent: 5834598 (1998-11-01), Lowman et al.
patent: 5859205 (1999-01-01), Adair et al.
patent: 5877293 (1999-03-01), Adair et al.
patent: 5929212 (1999-07-01), Jolliffe et al.
patent: 5994510 (1999-11-01), Adair et al.
patent: 6054297 (2000-04-01), Carter et al.
patent: 6054561 (2000-04-01), Ring
patent: 6180370 (2001-01-01), Queen et al.
patent: 6350861 (2002-02-01), Co et al.
patent: 6407213 (2002-06-01), Carter et al.
patent: 6548640 (2003-04-01), Winter
patent: 6639055 (2003-10-01), Carter et al.
patent: 6719971 (2004-04-01), Carter et al.
patent: 6800738 (2004-10-01), Carter et al.
patent: 2004/0127688 (2004-07-01), Winter
patent: 2004/0192897 (2004-09-01), Winter
patent: 2004/0236078 (2004-11-01), Carter et al.
patent: 2007/0077243 (2007-04-01), Carter et al.
patent: 85058/91 (1992-03-01), None
patent: 125023 (1984-11-01), None
patent: 323806 (1989-07-01), None
patent: 327000 (1989-08-01), None
patent: 328404 (1989-08-01), None
patent: 338745 (1989-10-01), None
patent: 365209 (1990-04-01), None
patent: 365997 (1990-05-01), None
patent: 368684 (1990-05-01), None
patent: 403156 (1990-12-01), None
patent: 438310 (1991-07-01), None
patent: 438312 (1991-07-01), None
patent: 440351 (1991-08-01), None
patent: 0 460 167 (1991-12-01), None
patent: 0 519 596 (1992-12-01), None
patent: 0531539 (1993-03-01), None
patent: 0 592 106 (1994-04-01), None
patent: 0 239 400 (1994-08-01), None
patent: 620276 (1994-10-01), None
patent: 682040 (1995-11-01), None
patent: 451216 (1996-01-01), None
patent: 432249 (1996-09-01), None
patent: 549581 (1997-01-01), None
patent: 0 120 694 (2002-02-01), None
patent: 2 1888941 (1987-10-01), None
patent: WO 87/02671 (1987-05-01), None
patent: WO 88/09344 (1988-12-01), None
patent: WO 8901783 (1989-03-01), None
patent: WO 89/06692 (1989-07-01), None
patent: WO 89/09622 (1989-10-01), None
patent: WO 90/13637 (1990-04-01), None
patent: WO 90/07861 (1990-07-01), None
patent: WO 91/07492 (1991-05-01), None
patent: WO 91/07500 (1991-05-01), None
patent: WO 91/09966 (1991-07-01), None
patent: WO 91/09967 (1991-07-01), None
patent: WO 91/09968 (1991-07-01), None
patent: WO 92/01047 (1992-01-01), None
patent: WO 92/04380 (1992-03-01), None
patent: WO 92/04381 (1992-03-01), None
patent: WO 92/05274 (1992-04-01), None
patent: WO 92/11383 (1992-07-01), None
patent: WO 92/11018 (1992-09-01), None
patent: WO 92/15683 (1992-09-01), None
patent: WO 92/16562 (1992-10-01), None
patent: WO 92/22653 (1992-12-01), None
patent: WO 93/02191 (1993-02-01), None
patent: WO 93/07461 (1993-04-01), None
patent: 94/11509 (1994-05-01), None
patent: WO 94/12214 (1994-06-01), None
patent: WO 99/60023 (1999-11-01), None
Draber, et al., “Stability of monoclonal IgM antibodies freeze-dried in the presence of trehalose”, Journal of Immunological Methods, 181: 37-43, (1995).
Adair et al., “Humanization of the murine anti-human CD3 monoclonal antibody OKT3”Hum. Antibod. Hybridomas5:41-47 (1994).
Amit et al., “Three-Dimensional Structure of an Antigen-Antibody Complex at 2.8 A Resolution”Science233:747-753 (Aug. 1986).
Amzel and Poljak, “Three-dimensional structure of immunoglobulins”Ann. Rev. Biochem.48:961-997 (1979).
Amzel et al., “The Three Dimensional Structure of a Combining Region-Ligand Complex of Immunoglobulin NEW at 3.5-A Resolution”Proc. Natl. Acad. Sci. USA71 (4) :1427-1430 (Apr. 1974).
Baselga et al., “Phase II Study of Weekly Intravenous Recombinant Humanized Anti-p185HER2Monoclonal Antibody in Patients With HER2
eu-Overexpressing Metastatic Breast Cancer”J. Clin. Oncol.14 (3) :737-744 (Mar. 1996).
Beverley & Callard, “Distinctive functional characteristics of human “T” lymphocytes defined by E rosetting or a monoclonal anti-T cell antibody”European Journal of Immunology11:329-334 (1981).
Bindon et al., “Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q”Journal of Experimental Medicine168(1):127-142 (Jul. 1988).
“Biosym Technologies in New Products, Chemical Design Automation 3” (Dec. 1988).
Bird et al., “Single-Chain Antigen-Binding Proteins”Science242:423-426 (Oct. 1988).
Boon, T., “Toward a genetic analysis of tumor rejection antigens”Advances in Cancer Research58:177-210 (1992).
Boulianne et al., “Production of functional chimaeric mouse/human antibody”Nature312:643-646 (Dec. 13, 1984).
Brennan et al., “Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin G1fragments”Science229(4708):81-83 (Jul. 5, 1985).
Brown et al., “Anti-Tac-H, a humanized antibody to the interleukin 2 receptor, prolongs primate cardiac allograft survival”Proc. Natl. Acad. Sci. USA88:2663-2667 (Apr. 1991).
Brown, Jr. et al., “Anti-Tac-H, a humanized antibody to the interleukin 2 receptor, prolongs primate cardiac allograft survival”Proc. Natl. Acad. Sci. USA88:2663-2667 (1991).
Bruccoleri et al., “Structure of antibody hypervariable loops reproduced by a conformational search algorithm”Nature335:564-568 (Oct. 1988).
Bruccoleri, “Structure of antibody hypervariable loops reproduced by a conformational search algorithm”Nature336:266 (1988).
Bruggemann, M. et al., “Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies”Journal of Experimental Medicine166:1351-1361 (1987).
Burgess et al., “Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue”Journal of Cell Biology111:2129-2138 (Nov. 1990).
Caron et al., “Biological and Immunological Features of Humanized M195 (Anti-CD33) Monoclonal Antibodies”Cancer Research52:6761-6767 (Dec. 1992).
Carter et al., “Hig LevelEscherichia coliExpression and Production of a Bivalent Humanized Antibody Fragment”Bio/Technology10(2):163-167 (Feb. 1992).
Carter et al., “Humanization of an Anti-p185HER2Antibody For Human Cancer Therapy”Proc. Natl. Acad. Sci. USA89(10):4285-4289 (May 1992).
Carter et al., “Improved Oligonucleotide Site-Directed Mutagenesis Using M13 Vectors”Nucl. Acids Res.13(12):4431-4443 (1985).
Carteron et al., “Treatment of Murine Lupus with F(ab')2 Fragments of Monoclonal Antibody to L3T4 (Suppression of Autoimmunity Does Not Depend on T Helper Cell Depletion)”J Immunol142(5):1470-1475 (Mar. 1, 1999).
Casale et al., “Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis”J. Allergy Clin. Immunol.100:110-121 (1997).
Cheetham, J., “Reshaping the antibody combining site by CDR replace
Carter Paul J.
Presta Leonard G.
Arnold & Porter LLP
Dreger Ginger R.
Genentech Inc.
Goddard Laura B
Marschang Diane
LandOfFree
Method for making humanized antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for making humanized antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for making humanized antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4295044